Friday 6 November 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue: +21.8%
EPS: −80.6%
Free cash flow: +6.78%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

44.15 0.39 −0.88%

Follow ALKS

Alert me

Market cap: $7.5B
P/E: 0.0×
Fwd P/E: −85.9×
Dividend yield: —
F-score: 7/9
Altman Z: 5.33
Beneish M: −3.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Alkermes plc (ALKS) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Alkermes plc (ALKS) trades at a P/S ratio of 4.3×. Over the past ten years it has ranged from 1.6× (March 2020) to 18.8× (December 2015); the current reading is higher than 61% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ALKS/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Alkermes plc P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ALKS/metrics/ps-ratio">Alkermes plc (ALKS) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	3.1×	2.25%
FY2024	3.1×	6.78%
FY2023	2.9×	(19.35%)
FY2022	3.5×	19.46%
FY2021	3.0×	4.57%
FY2020	2.8×	11.46%
FY2019	2.5×	(34.59%)
FY2018	3.9×	(55.39%)
FY2017	8.7×	(17.71%)
FY2016	10.6×	(43.72%)

Period	P/S ratio	Change
Sep 2026	3.9×	(26.09%)
Jun 2026	5.2×	39.52%
Mar 2026	3.8×	20.47%
Dec 2025	3.1×	(4.09%)
43 more quarters	Free account

Against its own ten years

Low 1.6× High 18.8×

Ten-year median 3.6×

Current reading's percentile 66

Company	P/S ratio
AMRX AMNEAL PHARMACEUTICALS, INC. compare	2.0×
HIMS Hims & Hers Health, Inc. compare	2.2×
ELAN Elanco Animal Health Incorporated compare	2.4×
SUPN Indivior Pharmaceuticals Inc. compare	2.4×
RDY Dr. Reddy's Laboratories Ltd compare	3.6×
LNTH Lantheus Holdings, Inc. compare	4.2×
ALKS Alkermes plc	4.3×
KNSA Kiniksa Pharmaceuticals International, plc compare	7.3×
LQDA Liquidia Corporation compare	8.8×
Drug Manufacturers Specialty & Generic industry median	2.1×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Alkermes plc (ALKS) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ALKS

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ALKS

Stockrow Weekly